Literature DB >> 22050374

Interleukin-6 in oral diseases: a review.

L Nibali1, S Fedele, F D'Aiuto, N Donos.   

Abstract

Interleukin-6 (IL-6) is a pleomorphic cytokine involved in a number of physiologic and pathologic processes including response to trauma and infection and development and progression of inflammation and malignancy. IL-6 is emerging as an important mediator and novel therapeutic target for chronic inflammatory diseases and cancer. The present study reviews the available evidence regarding the association between IL-6 and a range of oral diseases including infections (periodontal disease and endodontic infections), immunologically mediated disorders (oral lichen planus and Sjögren's syndrome) and malignancy (oral cancer and precancer). The role of common genetic variants of IL-6 in determining individual susceptibility to certain oral diseases, as well as novel therapeutic strategies based on IL-6 inhibition are also discussed.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22050374     DOI: 10.1111/j.1601-0825.2011.01867.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  47 in total

1.  Porphyromonas gulae Has Virulence and Immunological Characteristics Similar to Those of the Human Periodontal Pathogen Porphyromonas gingivalis.

Authors:  Jason C Lenzo; Neil M O'Brien-Simpson; Rebecca K Orth; Helen L Mitchell; Stuart G Dashper; Eric C Reynolds
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

2.  Streptococcus gordonii programs epithelial cells to resist ZEB2 induction by Porphyromonas gingivalis.

Authors:  Jun Ohshima; Qian Wang; Zackary R Fitzsimonds; Daniel P Miller; Maryta N Sztukowska; Young-Jung Jung; Mikako Hayashi; Marvin Whiteley; Richard J Lamont
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-10       Impact factor: 11.205

3.  Shifting the paradigm from inhibitors of inflammation to resolvers of inflammation in periodontitis.

Authors:  Thomas E Van Dyke
Journal:  J Periodontol       Date:  2020-06-20       Impact factor: 6.993

4.  Identifying the association between interleukin-6 and lichen planus: A meta-analysis.

Authors:  Meng Yin; Guifeng Li; Hui Song; Song Lin
Journal:  Biomed Rep       Date:  2017-04-07

5.  Minority stress and inflammatory mediators: covering moderates associations between perceived discrimination and salivary interleukin-6 in gay men.

Authors:  David Matthew Doyle; Lisa Molix
Journal:  J Behav Med       Date:  2016-08-17

6.  Interaction of tobacco chewing and smoking habit with interleukin 6 promoter polymorphism in oral precancerous lesions and oral cancer.

Authors:  Yadvendra Shahi; Sayali Mukherjee; Fahad M Samadi
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-27       Impact factor: 2.503

7.  Salivary cytokines as a minimally-invasive measure of immune functioning in young children: correlates of individual differences and sensitivity to laboratory stress.

Authors:  Jenna L Riis; Douglas A Granger; Janet A DiPietro; Karen Bandeen-Roche; Sara B Johnson
Journal:  Dev Psychobiol       Date:  2015-01-21       Impact factor: 3.038

8.  Niobium pentoxide as radiopacifying agent of calcium silicate-based material: evaluation of physicochemical and biological properties.

Authors:  Guilherme F Silva; Mário Tanomaru-Filho; Maria I B Bernardi; Juliane M Guerreiro-Tanomaru; Paulo S Cerri
Journal:  Clin Oral Investig       Date:  2015-02-03       Impact factor: 3.573

9.  Salivary and serum interleukin-6 levels in proliferative verrucous leukoplakia.

Authors:  Leticia Bagan; Guillermo T Sáez; M Carmen Tormos; Carlos Labaig-Rueda; Judith Murillo-Cortes; Jose V Bagan
Journal:  Clin Oral Investig       Date:  2015-08-09       Impact factor: 3.573

10.  A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjögren's syndrome.

Authors:  Sarah Benchabane; Abdelhalim Boudjelida; Ryma Toumi; Houda Belguendouz; Pierre Youinou; Chafia Touil-Boukoffa
Journal:  Int J Immunopathol Pharmacol       Date:  2016-05-19       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.